

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: William F. Crismore et al.Application No./Patent No./Control No.: 10/692,031Filed/Issue Date: 10/23/2003Entitled: ELECTROCHEMICAL BIOSENSOR TEST STRIPRoche Diagnostics Operations, Inc.

(Name of Assignee)

, a

Corporation

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title, and interest
(The extent (by percentage) of its ownership interest is 50%)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a true copy of the original assignment is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:


1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or currently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature

December 21, 2007

Date

Thomas Q. Henry, Reg. No. 28,309

Typed or printed name

(317) 634-3456

Telephone Number

Appointed Practitioner to Act on Behalf of Assignee

Title

For: ☒ U.S. and/or ☒ Foreign Rights
 For: ☒ U.S. Application or ☒ U.S. Patent
 By: Multiple Inventors

ASSIGNMENT OF INVENTION

For consideration,

ASSIGNORS (inventors):

<u>William F. Crismore</u> <i>Name</i>	<u>1215 N. Leland Avenue, Indianapolis, IN 46219</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Nigel A. Surridge</u> <i>Name</i>	<u>1248 E. 90th Street, Indianapolis, IN 46240</u> <i>Address</i>	<u>U.K.</u> <i>Nationality</i>
<u>Daniel R. McMinn</u> <i>Name</i>	<u>10517 Greenway Drive, Fishers, IN 46038</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Richard J. Bodensteiner</u> <i>Name</i>	<u>5014 Central Avenue, Indianapolis, IN 46205</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Eric R. Diebold</u> <i>Name</i>	<u>12580 Ensley Drive, Fishers, IN 46038</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>R. Dale Delk</u> <i>Name</i>	<u>1605 S. Stockport Drive, Muncie, IN 47304</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>David W. Burke</u> <i>Name</i>	<u>1931 Madison Court, Carmel, IN 46032</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Jiaxiong Jason Ho</u> <i>Name</i>	<u>5275 Ivy Hill Drive, Carmel, IN 46033</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Robert Kitchel Earl</u> <i>Name</i>	<u>12598 Spring Violet Place, Carmel, IN 46033</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
<u>Brian A. Heald</u> <i>Name</i>	<u>10337 Scavage Drive, Fishers, IN 46038</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>

hereby sell, assign and transfer to

ASSIGNEE:

<u>Boehringer Mannheim Corporation</u> <i>Name</i>	<u>9115 Hague Road, Indianapolis, IN 46250</u> <i>Address</i>	<u>U.S.</u> <i>Nationality</i>
---	--	-----------------------------------

and the successors, assigns and legal representatives of the ASSIGNEE (complete one of the following)

- ☒ the entire right, title and interest
☐ an undivided _____ percent (____%) interest

for the United States and its territorial possessions (check the following box if foreign rights are also to be assigned)

[X] and in all foreign countries, including all rights to claim priority

in and to any and all improvements which are disclosed in the invention entitled:

IMPROVED ELECTROCHEMICAL BIOSENSOR TEST STRIP

(check and complete (a), (b), (c) or (d))

and which is found in

- (a) ☐ U.S. patent application executed on even date herewith
(b) ☐ U.S. patent application executed on _____
 ☐ To comply with 37 CFR 3.21 for recordal of this assignment, I, an ASSIGNOR signing below, hereby authorize and request my attorney, as named in the Declaration and Power of Attorney I executed for this invention on the execution date stated above, to insert below the filing date and application number when it becomes known.
(c) [X] U.S. application serial no. 08/985,840 filed on December 5, 1997.
(d) ☐ U.S. patent no. _____ issued _____
 ☐ A change of address to which correspondence is to be sent regarding patent maintenance fees is being sent separately.

(CHECK (E) IF FOREIGN APPLICATION(S) IS ALSO BEING ASSIGNED)

(e) [X] and any legal equivalent thereof in a foreign country, including the right to claim priority

and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, We have hereunto set hand and seal this _____
(Date of signing).

WARNING: Date of signing must be the same as the date of execution of the application if item (a) was checked above.

William F. Crismore
Name

William F. Crismore 5-4-98
Signature

Nigel A. Surridge
Name

Nigel A. Surridge 5/13/98
Signature

Daniel R. McMinn
Name

Daniel R. McMinn 5/4/98
Signature

Richard J. Bodensteiner
Name

Richard J. Bodensteiner 5-4-98
Signature

Eric R. Diebold
Name

Eric R. Diebold 5-4-98
Signature

R. Dale Delk
Name

R Dale Delk 5-8-98
Signature

David W. Burke
Name

David W Burke 5-6-98
Signature

Jiaxiong Jason Ho
Name

Jiaxiong Jason Ho 5-1-98
Signature

Robert Kitchel Earl
Name

Robert Kitchel Earl 5-14-98
Signature

Brian A. Heald
Name

Brian A Heald 5/14/98
Signature

NOTE: No witnessing, notarization or legalization is necessary. If the assignment is notarized or legalized then it will only be prima facie evidence of execution 35 USC 261. Use next page if notarization is desired.

☐ Notarization or Legalization Page Added.

198706-883

ARTICLES OF MERGER
OF
ROCHE DIAGNOSTIC SYSTEMS, INC. 1988110794
INTO
BOEHRINGER MANNHEIM CORPORATION
(effective December 31, 1998) 198706-883

In accordance with the requirements of the Indiana Business Corporation Law, the undersigned corporations, desiring to effect a merger, set forth the following facts:

ARTICLE I - SURVIVING CORPORATION

Section 1: The name of the corporation surviving the merger is ROCHE DIAGNOSTICS CORPORATION and such name has been changed (from Boehringer Mannheim Corporation) as a result of the merger.

Section 2: The surviving corporation is a domestic corporation existing pursuant to the provisions of the Indiana Business Corporation Law, incorporated on June 25, 1987.

ARTICLE II - MERGING CORPORATION

The name, state of incorporation and date of qualification to do business in Indiana of the merging corporation is as follows:

Name:	Roche Diagnostic Systems, Inc.
State of Incorporation:	New Jersey
Date of Qualification in Indiana:	November 23, 1988

ARTICLE III - PLAN OF MERGER


The Plan of merger, containing such information as required by Section 23-1-40-1-(b) of the Indiana Business Corporation Law, is set forth on Exhibit A attached hereto and made a part hereof.

ARTICLE IV - MANNER OF ADOPTION AND VOTE

1. Action by Surviving Corporation. The outstanding capital stock of the surviving corporation consists of 1,000 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

2. Action by Merging Corporation. The outstanding capital stock of the merging corporation consists of 100 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

IN WITNESS WHEREOF, the undersigned being the President of Boehringer Mannheim Corporation, executes these Articles of Merger and verifies, subject to penalties of perjury, that the statements contained herein are true this 11th day of December, 1998.

A handwritten signature in dark ink, appearing to read "Dennert O. Ware", is written over a horizontal line.

Dennert O. Ware
President

AGREEMENT AND PLAN OF MERGER
OF
ROCHE DIAGNOSTIC SYSTEMS, INC.
INTO
BOEHRINGER MANNHEIM CORPORATION

AGREEMENT AND PLAN OF MERGER dated December 11, 1998 between Boehringer Mannheim Corporation, an Indiana corporation ("BMC"), and Roche Diagnostic Systems, Inc., a New Jersey corporation ("RDS").

WITNESSETH:

WHEREAS, BMC is a corporation duly organized and existing under the laws of the State of Indiana; and

WHEREAS, RDS is a corporation duly organized and existing under the laws of the State of New Jersey; and

WHEREAS, the Boards of Directors of both BMC and RDS deem it advisable and in the best interests of their respective corporations that RDS be merged with and into BMC; now, therefore, it is agreed that

1. At the Effective Time (as that term is hereinafter defined), and upon the terms and conditions set forth in Section 3 below, RDS shall be merged with and into BMC, with BMC as the surviving corporation in such merger (the "Surviving Corporation").

2. As to each constituent corporation, the designation and number of outstanding shares of each class and series and the voting rights thereof are as follows:

<u>Corporation</u>	<u>Designation and number of shares in each class or series outstanding</u>	<u>Shares entitled to vote</u>
RDS	Common Stock, 100 shares \$1.00 par value	100 shares
BMC	Common Stock, 1,000 shares, no par value	1,000 shares

3. The terms and conditions of the merger are as follows:

A. Share Cancellation. In view of the fact that a single shareholder owns all of the issued and outstanding capital stock of BMC and RDS, at the Effective Time each share of the Common Stock, par value \$1.00 per share, of RDS issued and outstanding immediately prior to

the Effective Time shall be automatically canceled and certificates for such shares shall be surrendered and canceled.

B. **Articles of Incorporation and By-Laws.** The Articles of Incorporation and By-Laws of BMC shall continue as the Articles of Incorporation and By-Laws of the Surviving Corporation; provided, however, that Article 1 of the Articles of Incorporation shall be amended to read; "The name of the Corporation is Roche Diagnostics Corporation."

C. **Shares of Surviving Corporation.** Each share of the Common Stock, no par value, of BMC issued and outstanding immediately prior to the Effective Time shall continue unchanged as one share of the stock of the Surviving Corporation, without the issuance or exchange of new shares or share certificates.

D. **Assets; Liabilities.** At the Effective Time, all the property, real and personal, rights, privileges, immunities, powers, purposes, franchises, patents, licenses, trademarks, registrations, causes of action, and every other asset of BMC and RDS shall be transferred to, vest in and devolve upon the Surviving Corporation, without further act or deed, and every interest of BMC and RDS shall be as effectively the property of the Surviving Corporation as they were of BMC and RDS, respectively. The Surviving Corporation shall assume and be liable for all liabilities, obligations, and penalties of BMC and RDS.

E. **Directors and Officers.** The directors and officers of the Surviving Corporation shall continue unchanged at and after the Effective Time.

F. **Abandonment.** Notwithstanding the approval and adoption of this Plan and Agreement of Merger by the sole stockholder of either or both BMC and RDS, this Agreement of Merger may be terminated at any time prior to the Effective Time by the Board of Directors of either BMC or RDS.

4. **Effective Time.** The merger of RDS into BMC shall be effective on December 31, 1998, and for accounting purposes shall be deemed to have occurred as of 11:59 p.m. on such date (the "Effective Time").

IN WITNESS WHEREOF, the undersigned have signed this Agreement as of the date first above written.

BOEHRINGER MANNHEIM CORPORATION

By: /s/ Dennert O. Ware
Name: Dennert O. Ware
Title: President

ROCHE DIAGNOSTIC SYSTEMS, INC.

By: /s/ Vincent P. Mihalik
Name: Vincent P. Mihalik
Title: Executive Vice President

**ASSET CONVEYANCE, GENERAL ASSIGNMENT
AND ASSUMPTION AGREEMENT**

This Asset Conveyance, General Assignment and Assumption Agreement (the "Agreement") effective as of January 1, 2004, is between Roche Diagnostics Corporation, an Indiana corporation ("RDC") and Roche Diagnostics Operations, Inc., a Delaware corporation ("RDOI"). RDC and RDOI are referenced individually as "Party" and collectively as "Parties".

WHEREAS, RDC deems it desirable to transfer certain assets and operations to its subsidiary RDOI for the purpose of aligning RDC's legal entity structure with local and global structure and accountabilities.

WHEREAS, this Agreement is necessary to evidence certain contributions to the capital of RDOI by RDC and to evidence the assumption of certain liabilities and obligations by RDOI.

WHEREAS, it is intended by the Parties that the exchange contemplated herein qualify for tax-free treatment under Section 351 of the Internal Revenue Code of 1986, as amended.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, RDC hereby assigns, transfers, conveys and delivers to RDOI free and clear of all liens (except as otherwise provided in Exhibit A), the following assets constituting personal property relating to or associated with the business to be conducted by RDOI:

- (a) Intangible Property. RDC's right, title and interest in and to all patents, patent applications, trademarks, and trademark applications listed on Exhibit B and all license agreements recited in Exhibit B to the extent those license agreements allow assignment from RDC to RDOI (the "Transferred Intellectual Property");
- (b) Transferred Contracts. RDC's right, title and interest in and to the contracts listed in Exhibit C to the extent those contracts may be assigned from RDC to RDOI (the "Transferred Contracts");
- (c) Tangible Personal Property Owned by RDC. RDC's right, title and interest in and to all tangible personal property listed in Exhibit D (the "Transferred Personal Property"); and
- (d) Tangible Personal Property Rented or Leased by RDC. RDC's leasehold interests and rights in and to the tangible personal property located in the Leased Premises and currently being leased or rented by RDC from a third party pursuant to the lease or rental agreements listed in Exhibit E (the "Personal Property Leases").

RDOI hereby assumes and agrees to perform RDC's obligations under the Transferred Contracts. RDC hereby assigns and conveys to RDOI any and all rights it may have to receive payments, revenues, or other receipts under the Transferred Contracts for work performed or services or materials provided under the Transferred Contracts after the date hereof and relinquishes any and all rights it may have to such payments, revenues, and receipts.

RDOI hereby assumes and agrees to perform RDC's obligations under the Personal Property Leases to the extent that the Personal Property Leases cover tangible personal property located in the Leased Premises. RDOI agrees to pay RDC RDOI's pro rata share of any and all payments due from RDC to a third party with respect to tangible personal property located in the Leased Premises.

RDC agrees that from time to time, whether on or after the date hereof, it will execute and deliver such other documents and take such other actions as may reasonably be required to transfer, assign and convey to RDOI more effectively the assets which are the subject of this Agreement.

This Agreement shall inure to the benefit of and shall be binding upon the parties, their successors and assigns.

This Agreement may be executed in separate counterparts, each of which when so executed shall be an original, but all of such counterparts shall constitute but one and the same instrument.


IN WITNESS WHEREOF, RDC and RDOI have executed this Asset Conveyance, General Assignment and Assumption Agreement as of the date first written above.

ROCHE DIAGNOSTICS CORPORATION

By: M. Madans

Printed: MARTIN MADANS

Title: President - CEO



ROCHE DIAGNOSTICS OPERATIONS, INC.

By: Ned J. Campbell

Printed: NED J. CAMPBELL

Title: President




ADDENDUM

This is an Addendum to subparagraph (a) Intangible Property of the "Asset Conveyance, General Assignment and Assumption Agreement", attached hereto:

"RDC's right, title and interest in any and all applications arising from the patents, patent applications listed in Exhibit B, including any and all divisionals, continuations, continuations-in-part thereof, and any and all patents to be issued and obtained therefor and thereon, United States and foreign, including all reissues and extensions thereof."

IN WITNESS WHEREOF, RDC and RDOI have agreed that this Addendum to the "Asset Conveyance, General Assignment and Assumption Agreement" is effective as of January 1, 2004.

ROCHE DIAGNOSTICS CORPORATION (RDC)

By: 

Printed: Lynn M. Gagel

Title: Assistant Secretary



ROCHE DIAGNOSTICS OPERATIONS, INC.
(RDOI)

By: 

Printed: Steve A. Oldham

Title: Vice President, General Counsel and Secretary



RDC PENDING REPORT

Case	Title	Country	Appl. No.	Appl. Date	Grant No.	Grant Date	Holder	Atty
19142 EP	Capillary hematocrit separation structure and method	EP	00123020.0	10/24/2000 0:00			ROCHE RDC INDI	SS
19137 EP	Embedded metallic deposits forming an electrode set for an e	EP	00123693.4	10/31/2000 0:00			ROCHE RDC INDI	SS
19083 EP	BIOSENSOR-APPARATUS	EP	00127129.5	12/12/2000 0:00			ROCHE RDC INDI	SS
19083 EP1	Biosensor	EP	00127129.5-2204	11/22/2000 0:00			ROCHE RDC INDI	SS
19147 EP	Thermally conductive sensor	EP	00127765.6	12/19/2000 0:00			ROCHE RDC INDI	SS
19146 EP	Microsphere containing sensor	EP	00127769.8	12/19/2000 0:00			ROCHE RDC INDI	SS
19148 EP	Cell for electrochemical analysis of a sample and method	EP	00127868.9	12/20/2000 0:00			ROCHE RDC INDI	SS
19149 EP	Cell for electrochemical analysis of a sample and method	EP	00127859.7	12/20/2000 0:00			ROCHE RDC INDI	SS
19091 EP	Hospital meter system	EP	00912044.5	8/21/2001 0:00			ROCHE RDC INDI	SS
19084 EP	ENZYMATIC MEASUREMENT OF MYCOPHENOLIC ACID	EP	00935908.4	5/11/2000 0:00			ROCHE RDC INDI	SS
19084 EP1	Enzymatic measurement of mycophenolic acid	EP	00935908.4-2116	1/23/2001 0:00			ROCHE RDC INDI	AM
19096 EP	Enzyme inhibition immunoassay	EP	00941723.9	2/12/2001 0:00			ROCHE RDC INDI	AM
19140 EP	METHOD, REAGENT AND TEST CARTRIDGE	EP	00957770.1	8/24/2000 0:00			ROCHE RDC INDI	HB
19082 EP	Electrochemical sensor and method for continuous analyte mon	EP	00965134.0	2/27/2002 0:00			ROCHE RDC INDI	SS
19085 EP	Laser defined features for patterned laminates and electrode	EP	00967259.3	3/11/2002 0:00			ROCHE RDC INDI	SS
19268 EP	Amperometric biosensor test strip	EP	00989267.0	5/17/2002 0:00			ROCHE RDC INDI	SS
22170 JP	Capillary stop-flow junction having improved stability again	JP	04-44588	3/21/1992 0:00			ROCHE RDC INDI	HB
18382 JP	Extender containing polymer compositions and uses thereof	JP	06-524393	4/21/1994 0:00			ROCHE RDC INDI	YM
22156 US1	Blood Separation Device under low pressure conditions	US	07/163392	3/21/1988 0:00			ROCHE RDC INDI	HB
19134 US1	Nucleic Acid Assay Method	US	07/483909	2/22/1990 0:00			ROCHE RDC INDI	HB
19130 US	Fluorescence Assay Apparatus	US	07/612869	11/13/1990 0:00			ROCHE RDC INDI	HB
19076 US	CAPILLARY MIXING DEVICE	US	07/867155	4/10/1992 0:00			ROCHE RDC INDI	HB
22113 US	Method and apparatus for measuring specific binding assays	US	07/980497	11/23/1992 0:00			ROCHE RDC INDI	HB
18711 US	NIR CALIBRATION	US	08/001950	8/7/1995 0:00			ROCHE RDC INDI	HB
19053 US	INSTRUMENT SETUP UTILITY PROGRAM	US	08/087499	12/4/1997 0:00			ROCHE RDC INDI	HB
19130 US1	Fluorescence assay apparatus	US	08/350669	12/7/1994 0:00			ROCHE RDC INDI	HB
22185 US	Immunoassay System	US	08/398717	8/25/1989 0:00			ROCHE RDC INDI	HB
18662 FR	Evanescent Wave Immunoassay system	FR	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 DE	Evanescent wave immunoassay system	DE	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 ES	Evanescent wave immunoassay system	ES	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 GB	Evanescent wave immunoassay system	GB	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 IT	Evanescent wave immunoassay system	IT	0815431	1/25/1996 0:00			ROCHE RDC INDI	HB
18662 JP	Evanescent wave immunoassay system	JP	08-528391	1/25/1996 0:00			ROCHE RDC INDI	HB
19163 US3	Liquid reagent set for L-lactate determination	US	09/006212	1/31/2002 0:00			ROCHE RDC INDI	AM

18210 US2	Reagent and assay methods including a phenazine-containing i	US	08/598181	2/7/1996 0:00	5707820	1/13/1998 0:00	ROCHE RDC INDI	YM
18436 US4	Fluid dose, flow and coagulation sensor for medical instrume	US	08/478409	6/7/1995 0:00	5710622	1/20/1998 0:00	ROCHE RDC INDI	HB
19136 US2	Multiplex immunoassay System	US	08/222113	4/4/1994 0:00	5719063	2/17/1998 0:00	ROCHE RDC INDI	HB
19001 FR	CRADLE FOR INSTRUMENT	FR	995192	8/18/1999 0:00	572209-57	2/18/2000 0:00	ROCHE RDC INDI	
18523 US1	Method and apparatus for automatic control of instruments th	US	08/423816	4/18/1995 0:00	5724066	3/3/1998 0:00	ROCHE RDC INDI	AM
18557 US2	Purified mixture of collagenase I, collagenase II, and two o	US	08/590957	1/24/1996 0:00	5753485	5/19/1998 0:00	ROCHE RDC INDI	WK
18667 US	Electrochemical biosensor test strip	US	08/496939	6/30/1995 0:00	5762770	6/9/1998 0:00	ROCHE RDC INDI	YM
18782 US1	Apparatus and method for conducting a binding assay on an ab	US	08/877189	6/17/1997 0:00	5770458	6/23/1998 0:00	ROCHE RDC INDI	HB
18436 US1	Fluid dose, flow and coagulation sensor for medical instrume	US	08/623872	3/29/1996 0:00	5789864	8/4/1998 0:00	ROCHE RDC INDI	HB
18437 US1	Power supply monitor and control for medical instrument	US	08/697019	8/16/1996 0:00	5792944	8/11/1998 0:00	ROCHE RDC INDI	HB
22129 US	Stable aqueous reagent containing NAD	US	08/791920	1/31/1997 0:00	5804403	9/8/1998 0:00	ROCHE RDC INDI	AM
18313 US	Assay using an unblocked solid phase with immobilized analyt	US	07/943897	9/11/1992 0:00	5807752	9/15/1998 0:00	ROCHE RDC INDI	WK
18312 US	Casing means for analytical test apparatus	US	07/940016	9/3/1992 0:00	5820826	10/13/1998 0:00	ROCHE RDC INDI	HB
18742 US	Enzyme composition for tissue dissociation	US	08/760893	12/6/1996 0:00	5830741	11/3/1998 0:00	ROCHE RDC INDI	WK
18435 US1	Analog heater control for medical instrument	US	08/554755	11/7/1995 0:00	5832921	11/10/1998 0:00	ROCHE RDC INDI	HB
18423 US	Magnet for medical instrument	US	08/114896	8/31/1993 0:00	5841023	11/24/1998 0:00	ROCHE RDC INDI	HB
18641 US1	Reagent including an osmium-containing redox mediator	US	08/770975	12/20/1996 0:00	5846702	12/8/1998 0:00	ROCHE RDC INDI	YM
21220 US1	Synchronized test system	US	08/960866	10/30/1997 0:00	5872713	2/16/1999 0:00	ROCHE RDC INDI	SS
21197 US1	Methods for applying a reagent to an analytical test device	US	09/004604	1/8/1998 0:00	5876957	3/2/1999 0:00	ROCHE RDC INDI	SS
21204 US1	Blood fluid sampling device and methods of use	US	08/857880	5/16/1997 0:00	5879311	3/9/1999 0:00	ROCHE RDC INDI	SS
21203 US4	Diagnostic compositions and devices utilizing same	US	09/037653	3/10/1998 0:00	5885790	3/23/1999 0:00	ROCHE RDC INDI	SS
18437 US2	Power supply monitor and control for medical instrument	US	08/963672	10/31/1997 0:00	5886252	3/23/1999 0:00	ROCHE RDC INDI	HB
19289 US	Detection of low level hydrophobic analytes in environmental	US	08/832168	4/2/1997 0:00	5891740	4/6/1999 0:00	ROCHE RDC INDI	HB
18388 US1	PROBENSAMMELUMSCHLAG	US	08/757374	11/27/1996 0:00	5895704	4/20/1999 0:00	ROCHE RDC INDI	YM
19078 US	Method of detecting organisms in a sample	US	08/985574	12/5/1997 0:00	5902722	5/11/1999 0:00	ROCHE RDC INDI	AM
18906 US	Diazonium assay reagents and methods for their use	US	08/975796	11/21/1997 0:00	5935861	8/10/1999 0:00	ROCHE RDC INDI	AM
18965 US	Phencyclidine analogs for immunoassay	US	09/032158	2/27/1998 0:00	5939332	8/17/1999 0:00	ROCHE RDC INDI	AM
18288 US	Detection of low level analytes in samples using agglutinati	US	08/831206	4/12/1997 0:00	5942442	8/24/1999 0:00	ROCHE RDC INDI	HB
18742 US1	Enzyme composition for tissue dissociation	US	09/184616	11/2/1998 0:00	5952215	9/14/1999 0:00	ROCHE RDC INDI	WK
18911 US	Procedure for subtractive hybridization and difference analy	US	08/823111	3/24/1997 0:00	5958738	9/28/1999 0:00	ROCHE RDC INDI	WK
21198 US1	Capillary fill test device with improved fluid delivery	US	08/961942	10/31/1997 0:00	5968765	10/19/1999 0:00	ROCHE RDC INDI	SS
19072 US	Capillary fill test device with improved fluid delivery	US	09/023671	2/13/1998 0:00	5975153	11/2/1999 0:00	ROCHE RDC INDI	HB
18733 US	Method for measuring antigen concentration	US	08/663922	6/14/1996 0:00	5981199	11/9/1999 0:00	ROCHE RDC INDI	WK
22156 AU	Blood separation device under low pressure conditions	AU	80439/87	10/28/1987 0:00	5983312	11/6/1990 0:00	ROCHE RDC INDI	HB
19032 US	Electrochemical biosensor test strip	US	08/985840	12/5/1997 0:00	5997817	12/7/1999 0:00	ROCHE RDC INDI	SS
21211 US1	Membrane based on electrochemical test device and related me	US	09/164405	9/30/1998 0:00	6001239	12/14/1999 0:00	ROCHE RDC INDI	SS
22185 US1	Immunoassay system	US	08/406380	3/17/1995 0:00	6008057	12/28/1999 0:00	ROCHE RDC INDI	HB

RDC GRANTED REPORT

Case	Title	Country	Appl. No.	Appl. Date	Grant No.	Grant Date	Holder	Atty
19127 FR1	Coagulation Characteristic Testing Instrument	FR	0295	4/28/1994 0:00	0295	9/30/1994 0:00	ROCHE RDC INDI	HB
19129 IT	Accessory box for cradle for Instrument (Design)	IT	TO990000246	8/31/1999 0:00	00075742	3/14/2002 0:00	ROCHE RDC INDI	SS
19126 FR	Coagulation characteristic testing instrument (Design)	FR	002033	3/30/2000 0:00	002033		ROCHE RDC INDI	HB
22181 FR	Assay Apparatus and Method	FR	84303759.9	6/5/1984 0:00	0128723	1/7/1993 0:00	ROCHE RDC INDI	HB
22181 GB	Assay Apparatus and Method.	GB	84303759.9	6/5/1984 0:00	0128723	1/7/1993 0:00	ROCHE RDC INDI	HB
19001 ES	Cradle for Instrument (Design)	ES	146290	9/1/1999 0:00	0146290	7/7/2000 0:00	ROCHE RDC INDI	SS
22153 CH	Capillary Flow Device	CH	0212314	7/24/1986 0:00	0212314	4/27/1994 0:00	ROCHE RDC INDI	HB
22153 GB	Capillary flow device	GB	0212314	7/24/1986 0:00	0212314	4/27/1994 0:00	ROCHE RDC INDI	HB
22153 IT	Capillary flow device	IT	0212314	7/24/1986 0:00	0212314	4/27/1994 0:00	ROCHE RDC INDI	HB
22151 AT	Integrated drug dosage form and metering system	AT	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 BE	Integrated drug dosage form and metering system	BE	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 CH	Integrated drug dosage form and metering system	CH	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 FR	Integrated drug dosage form and metering system	FR	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 GB	Integrated drug dosage form and metering system	GB	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 IT	Integrated drug dosage form and metering system	IT	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 LU	Integrated drug dosage form and metering system	LU	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22151 NL	Integrated drug dosage form and metering system	NL	86308307.7	10/24/1986 0:00	0224335	8/26/1992 0:00	ROCHE RDC INDI	HB
22113 DE	Method and apparatus for measuring specific binding assays	DE	86905538.4	8/21/1986 0:00	0233939	11/13/1991 0:00	ROCHE RDC INDI	HB
22113 FR	Method and apparatus for measuring specific binding assays	FR	86905538.4	8/21/1986 0:00	0233939	11/13/1991 0:00	ROCHE RDC INDI	HB
22113 GB	Method and apparatus for measuring specific binding assays	GB	86905538.4	8/21/1986 0:00	0233939	11/13/1991 0:00	ROCHE RDC INDI	HB
22113 IT	Method and apparatus for measuring specific binding assays	IT	86905538.4	8/21/1986 0:00	0233939	11/13/1991 0:00	ROCHE RDC INDI	HB
22156 BE	Blood separation device under low pressure conditions	BE	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 CH	Blood separation device under low pressure conditions	CH	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 FR	Blood separation device under low pressure conditions	FR	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 GB	Blood separation device under low pressure conditions	GB	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 IT	Blood separation device under low pressure conditions	IT	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 LU	Blood separation device under low pressure conditions	LU	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22156 NL	Blood separation device under low pressure conditions	NL	87309171.4	10/16/1987 0:00	0269240	9/9/1992 0:00	ROCHE RDC INDI	HB
22140 NL	Test piece coloration comparative decision unit (EVR III) (NL	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 FR	Test piece coloration comparative decision unit (EVR III) (FR	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 IT	Test piece coloration comparative decision unit (EVR III) (IT	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22140 GB	Test piece coloration comparative decision unit (EVR III) (GB	88112168.5-2107	7/27/1988 0:00	0301524	11/4/1992 0:00	ROCHE RDC INDI	YM
22160 CH	Apparatus and Method for Delution and mixing of Liquid	CH	0305210	8/26/1988 0:00	0305210	12/8/1993 0:00	ROCHE RDC INDI	HB
22160 FR	Apparatus and Method for Delution and mixing of Liquid	FR	0305210	8/26/1988 0:00	0305210	12/8/1993 0:00	ROCHE RDC INDI	HB